ArticleApplied and environmental microbiology2026
Engineering a T7 bacteriophage to attenuate LPS-driven inflammatory responses during bacteriolysis.
Article in Applied and environmental microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phage Therapy Is Partially Successful in Rescuing Hornworms fromAntibiotics (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial lysis during treatment of Gram-negative infections can release lipopolysaccharide (LPS) and aggravate inflammation. Here, we engineered two complementary T7 bacteriophages: T7- IMPORTANCE: Bacteriophage therapy is being reconsidered for treating drug-resistant Gram-negative infections, but there is concern that rapid bacterial lysis may release LPS and worsen inflammation. We used bacteriophage T7 as a platform to test whether bacteriophages can be engineered to both fight bacteria and soften these harmful host responses. First, we created a NanoLuc reporter bacteriophage that produces light only when it grows in live bacteria, confirming that engineered bacteriophages can deliver active proteins directly in infected animals. We then built a therapeutic T7-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.